glp 1 for non obese GLP-1 Agonists In Obesity Glucagon-Like Peptide-1: New Regulator in

In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea

These drugs induce a mean weight loss of 1.88kg and also lower blood pressure (mean: 2.46mmHg in systolic and 1.46mmHg in diastolic blood pressure).48 The EMPA-REG,49 CANVAS and CANVAS-R trials,50 conducted in patients with DM2 and high cardiovascular risk, showed empagliflozin and canagliflozin to reduce cardiovascular risk (including cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and hospital admission due to heart failure)

cerevisiae was utilized to keep uniform expression of each construct in this work

Enebo, L.B